Conflict of interest
SE, NTT
The authors declare the following financial interests/personal relationships, which may be considered potential competing interests: DT has received honoraria from Eli Lilly and Taiho. SE has received honoraria from Ono and Taiho. MN has received honoraria from Chugai and Yakult Honsha. AS has received honoraria from Chugai. NO has received honoraria from Bayer, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Ono, Taiho, and Takeda, and has participated in an advisory board of GlaxoSmithKline. SM has received grants from Canon Medical Systems, HUG Holdings, and NTT and has received honoraria from Novartis and Taiho. FN has received grants from Astellas, AstraZeneca, Chugai, Daiichi Sankyo, Eisai, J-pharma, Merck, Mochida, MSD, Ono, Sumitomo Pharma, Taiho, Takeda, and Yakult Honsha, and has received honoraria from Chugai, Daiichi Sankyo, MSD, and Taiho. KY has received grants from Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Ono, Taiho, and Takeda, and has received honoraria from Chugai and Taiho. All remaining authors have declared no conflicts of interest.